Karen Bick Sells 6,062 Shares of Ralliant (NYSE:RAL) Stock

Ralliant Corporation (NYSE:RAL) SVP Karen Bick sold 6,062 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $72.00, for a total transaction of $436,464.00. Following the sale, the senior vice president owned 31,668 shares in the company, valued at $2,280,096. The trade was a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ralliant Trading Down 4.2%

NYSE RAL opened at $66.56 on Thursday. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $75.41. The firm has a 50 day moving average of $69.02 and a two-hundred day moving average of $55.79. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. The stock has a market capitalization of $7.36 billion, a PE ratio of -6.13, a price-to-earnings-growth ratio of 2.58 and a beta of 1.60.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. The business had revenue of $567.80 million for the quarter. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, research analysts expect that Ralliant Corporation will post 2.87 EPS for the current fiscal year.

Ralliant Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 8th. Ralliant’s dividend payout ratio is currently -1.84%.

Hedge Funds Weigh In On Ralliant

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in Ralliant during the 2nd quarter worth $1,039,481,000. Dodge & Cox grew its holdings in shares of Ralliant by 13.3% during the fourth quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after buying an additional 1,434,376 shares during the last quarter. Viking Global Investors LP acquired a new position in Ralliant in the 2nd quarter valued at about $257,200,000. Millennium Management LLC increased its position in Ralliant by 172.4% in the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after acquiring an additional 3,147,660 shares during the period. Finally, State Street Corp purchased a new stake in Ralliant during the 2nd quarter valued at approximately $213,096,000.

Analyst Upgrades and Downgrades

Several brokerages have commented on RAL. Vertical Research lowered shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price target on the stock. in a research note on Wednesday, May 27th. Evercore initiated coverage on shares of Ralliant in a research report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price objective for the company. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a report on Friday, July 31st. BMO Capital Markets started coverage on shares of Ralliant in a research report on Monday, July 20th. They issued a “market perform” rating and a $78.00 target price on the stock. Finally, Zacks Research upgraded shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ralliant presently has an average rating of “Moderate Buy” and an average price target of $75.70.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.